12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Company News  |  Deals

Galderma, Nuvo deal

Nuvo will receive $6 million in milestone payments from Galderma under a 2008 deal granting Galderma exclusive, worldwide rights to Pliaglis lidocaine/tetracaine. The milestones were triggered by the first three EU approvals of Pliaglis...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >